A study looked at more than 23,600 Medicare beneficiaries with RA who had received a ≥30-day prescription of an opioid drug. Participants were grouped according to those who had been prescribed a ...

Please provide your email address to receive an email when new articles are posted on . Despite guidelines recommending early and aggressive therapy in RA, disease-modifying antirheumatic drug ...

Researchers found that risk of adverse events and mortality did not increase following certain rheumatoid arthritis (RA) treatments. Among individuals with rheumatoid arthritis (RA), beginning use of ...

Use of disease-modifying anti-rheumatic drugs (DMARDs) for rheumatoid arthritis (RA) was markedly lower among all major racial-ethnic minority groups in the U.S. compared with white patients, analysis ...

A scoping review shows machine learning models may help predict response to biologic and targeted synthetic DMARDs in ...

If you are over the age of 65 and have rheumatoid arthritis (RA), your physician may not be treating you as aggressively as recommended by American College of Rheumatology (ACR). Updated in 2021, the ...

Nonadherence to DMARDs in RA varies widely, with rates from 1.5% to 100% across different studies and DMARD classes. The review identified 31 unique nonadherence measures, with indirect methods like ...

There are several effective treatments for RA, including DMARDs and biologics. Both types of medications control rheumatoid arthritis by lowering the inflammation that fuels it, but there are ...

The treat-to-target approach represented a stepped-up model for chronic disease management that only became possible when the available therapies showed the potential for disease remission. The ...

Please provide your email address to receive an email when new articles are posted on . Sustained DMARD-free remission “does not seem attainable” for patients with RA requiring biological DMARDs, but ...

Iguratimod is an emerging disease‐modifying antirheumatic drug (DMARD) that has attracted attention due to its dual ability to control inflammatory pathways and provide bone protection in rheumatoid ...